{
    "2021-07-20": [
        [
            {
                "time": "",
                "original_text": "又一基金名将认错与反思：迎来历史上业绩最差季度，朱少醒、梁浩、袁芳、陈皓、归凯等各自亮出最新持仓",
                "features": {
                    "keywords": [
                        "基金",
                        "业绩",
                        "最差季度",
                        "朱少醒",
                        "梁浩",
                        "袁芳",
                        "陈皓",
                        "归凯"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "金融"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "此外，在政策、人才回流等多重因素推动下，我国创新药研发火热，这也进一步促进了我国CXO行业发展。",
                "features": {
                    "keywords": [
                        "政策",
                        "人才回流",
                        "创新药",
                        "研发",
                        "CXO行业"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "黄金赛道CXO|从实验室化学到CXO“全家桶”，康龙化成要向药明康德看齐？",
                "features": {
                    "keywords": [
                        "CXO",
                        "康龙化成",
                        "药明康德"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "速读社丨GSK公布4亿英镑英国研发设施扩建计划 罗氏/再生元新冠中和抗体疗法在日本获批上市",
                "features": {
                    "keywords": [
                        "GSK",
                        "研发设施",
                        "扩建",
                        "罗氏",
                        "再生元",
                        "新冠",
                        "中和抗体",
                        "日本"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药行业周报：中报预告持续发布 关注业绩高增长个股",
                "features": {
                    "keywords": [
                        "医药行业",
                        "中报预告",
                        "业绩高增长"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "【券商聚焦】招商香港升药明康德(02359)目标价至250港元 重申“买入”评级",
                "features": {
                    "keywords": [
                        "券商",
                        "招商香港",
                        "药明康德",
                        "目标价",
                        "买入评级"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业周观点：中报业绩陆续披露 关注基本面变动",
                "features": {
                    "keywords": [
                        "医药生物",
                        "中报业绩",
                        "基本面变动"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "傅鹏博、赵枫、冯明远等顶流基金经理最新重仓股曝光",
                "features": {
                    "keywords": [
                        "傅鹏博",
                        "赵枫",
                        "冯明远",
                        "基金经理",
                        "重仓股"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "金融"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "康龙化成(300759)：H1收入持续提速 运营效率提升拉动业绩大幅增长",
                "features": {
                    "keywords": [
                        "康龙化成",
                        "H1收入",
                        "运营效率",
                        "业绩增长"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "【2359】药明康德6高层拟三个月内减持33万股A股|头条金融网 拟减持股份数量",
                "features": {
                    "keywords": [
                        "药明康德",
                        "高层",
                        "减持",
                        "A股"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "药明康德(603259)：H1业绩超预期 临床研究及CDMO业务增长强劲",
                "features": {
                    "keywords": [
                        "药明康德",
                        "H1业绩",
                        "临床研究",
                        "CDMO业务",
                        "增长强劲"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "康臣药业（1681.HK）：与药明康德强强联合，奠定全方位肾科龙头地位",
                "features": {
                    "keywords": [
                        "康臣药业",
                        "药明康德",
                        "肾科",
                        "龙头地位"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "刘格菘仓位仍超90%、萧楠大幅增持银行股",
                "features": {
                    "keywords": [
                        "刘格菘",
                        "萧楠",
                        "银行股",
                        "增持"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "金融"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "速递 | 开发下一代KRAS抑制剂，新锐完成近9000万美元B轮融资",
                "features": {
                    "keywords": [
                        "KRAS抑制剂",
                        "新锐",
                        "融资"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "速递 | 同时靶向TIGIT、PD-1和PVRIG三种免疫检查点，联合疗法完成首例给药",
                "features": {
                    "keywords": [
                        "TIGIT",
                        "PD-1",
                        "PVRIG",
                        "免疫检查点",
                        "联合疗法",
                        "首例给药"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "重仓股“大换血”，二季报显露基金大咖“新宠”",
                "features": {
                    "keywords": [
                        "重仓股",
                        "二季报",
                        "基金大咖",
                        "新宠"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "金融"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}